Document is current
Any future updates will be listed below
-
Authors
Gao, Huanhuan
Zhan, Yuecheng
Liu, Yuanqi
Zhu, Zhiyi
Zheng, Yuxiu
Qian, Liqin
Xue, Zhangzhi
Cheng, Honghan
Nie, Zongxiang
Ge, Weigang https://orcid.org/0000-0002-1803-4327
Ruan, Senlin
Liu, Jiaxu
Zhang, Jikai
Sun, Yingying
Zhou, Lei
Xun, Dongyue
Wang, Yingrui https://orcid.org/0000-0001-5532-3454
Xu, Heyun
Miao, Huiwen https://orcid.org/0000-0001-6329-9511
Zhu, Yi https://orcid.org/0000-0003-0429-0802
Guo, Tiannan https://orcid.org/0000-0003-3869-7651
-
Funding
Funding for this research was provided by:
Noncommunicable Chronic Diseases-National Science and Technology Major Project (2024ZD0533300)
Pioneer and Leading Goose R&D Program of Zhejiang (2023C03056,2024SSYS0035)
National Key R&D Program of China (2022YFF0608403)
National Natural Science Foundation of China (82303849)
- License Information
-
More Information
Article History
Received: 10 November 2025
Revised: 12 November 2025
Accepted: 13 November 2025
First Online: 5 December 2025
Disclosure and competing interests statement
: TG and YZ are shareholders of Westlake Omics (Hangzhou) Biotechnology Co., Ltd., where OmniProt and related technologies are commercialized. Two patents related to Baize technologies have been filed, with the application numbers CN 202510492870.3 and CN 202510492911.9. ZZ, WG, YC, and YZ are employed by Westlake Omics (Hangzhou) Biotechnology Co., Ltd. The remaining authors declare no competing interests.
